Skip to content

Study · Other design · 2014

1 result

[Pharmacokinetics of three peroral dosage forms of new dipeptide anxiolytic drug GB-115].

Ivannikova EV, Boĭko SS, Zherdev VP, Raskin SIu, Blynskaia EV, Turchinskaia KG, Illarionov AA

Eksperimental'naia i klinicheskaia farmakologiia1 Jan 2014

PMID25322652 (opens in a new tab)PepBankPUB-25322652
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalOther designPharmacokinetics

    In an unspecified model, GB‑115 drug form No. 2 had relative bioequivalence of 192%, exceeding the parent substance and other forms.

    In plain wordsIn an unspecified model, GB‑115 form No. 2 had higher relative bioequivalence than the parent substance and other forms.

    Peptide
    GB-115
    Outcome
    IncreaseRelative bioequivalence of drug form No. 2
    Study

    n: not reported in source

    Comparator
    Micronized parent substance and two other drug forms
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · peroralAs given in this study.

    Measurements

    Relative bioequivalence
    192%
    drug form No. 2
    Bioequivalence
    53%
    other drug form
    Bioequivalence
    117%
    other drug form

    Source sentences

    Summary
    As a result of the investigations of GB-115 pharmacokinetics, drug form No. 2 (with a relative bioequivalence of 192%) showed advantages in comparison to the micronized parent substance and two other drug forms (bioequivalence, 53 and 117%) and can be recommended for further pharmacological studies.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.